AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26063067 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin B-6
Number of subjects: 368
Study 26063067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary folate
Number of subjects: 368
Study 26063067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin B-6
Number of subjects: 368
Study 26063067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary choline
Number of subjects: 368
Study 26063067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sources of folate
Number of subjects: 368
Study 26063067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sources of vitamin B-6
Number of subjects: 368
Study 26063067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sources of vitamin B-12
Number of subjects: 368
Study 26063125 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal resuscitation for hospital deliveries (4.8%)
Number of subjects: 7
Study 26063125 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm births
Number of subjects: 7
Study 26063125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (<2500g)
Number of subjects: 7
Study 26063125 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age > 35 and <20 years
Number of subjects: 7
Study 26063125 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender, multiple gestation, major congenital anomalies, breech presentation/transverse lie, and no antenatal care
Number of subjects: 7
Study 26063125 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population rate of evidence-based interventions
Number of subjects: 7
Study 26063292 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 269614
Study 26063291 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of breastfeeding
Number of subjects: 255495
Study 26063291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding at 42 days post-partum
Number of subjects: 255495
Study 26063291 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with failure to initiate early breastfeeding
Number of subjects: 255495
Study 26063291 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with failure to achieve exclusive breastfeeding at 42 days
Number of subjects: 255495
Study 26063346 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern contraceptive usage
Number of subjects: 36687
Study 26063346 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraceptives (intrauterine devices)
Number of subjects: 36687
Study 26063346 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions aimed at increasing effective contraceptive methods
Number of subjects: 36687
Study 26063350 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent mothers aged 15-19 years
Number of subjects: 269273
Study 26063350 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent mothers aged <15 years
Number of subjects: 269273
Study 26063350 — intervention group
Group type: COMPARATOR
Intervention: Adults aged 20-24 years
Number of subjects: 269273
Study 26063475 — intervention group
Group type: EXPERIMENTAL
Intervention: SSE training intervention
Number of subjects: 274
Study 26063483 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care attendance
Number of subjects: 0
Study 26063483 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester antenatal care initiation
Number of subjects: 0
Study 26063483 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of antenatal care visits
Number of subjects: 0
Study 26063483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid coverage
Number of subjects: 0
Study 26063483 — intervention group
Group type: EXPERIMENTAL
Intervention: Syphilis screening
Number of subjects: 0
Study 26063483 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia screening
Number of subjects: 0
Study 26063483 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing
Number of subjects: 0
Study 26063483 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth preparation
Number of subjects: 0
Study 26063483 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventative and screening interventions coverage
Number of subjects: 0
Study 26063633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib as a single agent
Number of subjects: 44
Study 26063768 — intervention group
Group type: EXPERIMENTAL
Intervention: High marine n-3 polyunsaturated fatty acid levels (≥7.95 weight percentage)
Number of subjects: 1990
Study 26063768 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper quartile of marine n-3 polyunsaturated fatty acid levels
Number of subjects: 1990
Study 26063768 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of marine n-3 polyunsaturated fatty acids
Number of subjects: 1990
Study 26063768 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of eicosapentaenoic acid (a type of marine n-3 polyunsaturated fatty acid)
Number of subjects: 1990
Study 26063768 — intervention group
Group type: COMPARATOR
Intervention: Total or individual marine n-3 polyunsaturated fatty acid levels
Number of subjects: 1990
Study 26063893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 85
Study 26063893 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 85
Study 26063893 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole + Cyclophosphamide
Number of subjects: 85
Study 26063893 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole + Cyclophosphamide + Sorafenib
Number of subjects: 85
Study 26063893 — intervention group
Group type: EXPERIMENTAL
Intervention: RDA (RNA disruption assay)
Number of subjects: 85
Study 26064113 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week continuous administration of a protein-based formula (1.2 g/kg of ideal body weight/day) by nasogastric tube
Number of subjects: 364
Study 26064113 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week continuous administration of a protein-based formula
Number of subjects: 364
Study 26064192 — intervention group
Group type: EXPERIMENTAL
Intervention: semagacestat (γ-secretase inhibitor)
Number of subjects: 0
Study 26064192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26065566 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (adenotonsillectomy)
Number of subjects: 117
Study 26065566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment
Number of subjects: 117
Study 26065566 — intervention group
Group type: COMPARATOR
Intervention: No treatment (non-OSAS)
Number of subjects: 117
Study 26065566 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure treatment
Number of subjects: 117
Study 26065566 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a risk factor for residual OSAS in surgically treated children
Number of subjects: 117
Study 26065566 — intervention group
Group type: EXPERIMENTAL
Intervention: RDI at T0 and increase in BMI as risk factors for persistent OSAS in dietary treatment
Number of subjects: 117
Study 26065651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib plus multiagent chemotherapy (vincristine, daunorubicin, prednisolone) during induction treatment
Number of subjects: 90
Study 26065651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib maintenance after consolidation or allo-HCT
Number of subjects: 90
Study 26065651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib plus multiagent chemotherapy
Number of subjects: 90
Study 26065651 — intervention group
Group type: COMPARATOR
Intervention: Subjects that failed to achieve MR3 or MR5
Number of subjects: 90
Study 26065651 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD statuses just before allo-HCT and at 3 months after allo-HCT
Number of subjects: 90
Study 26065651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib combined with high-dose cytotoxic drugs
Number of subjects: 90
Study 26065651 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD status at early postremission time
Number of subjects: 90
Study 26066077 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously diagnosed patients
Number of subjects: 0
Study 26066077 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients
Number of subjects: 0
Study 26066077 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously diagnosed patients in FC I
Number of subjects: 0
Study 26066077 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously diagnosed patients in FC II
Number of subjects: 0
Study 26066077 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously diagnosed patients in FC III
Number of subjects: 0
Study 26066077 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously diagnosed patients in FC IV
Number of subjects: 0
Study 26066077 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients in FC I
Number of subjects: 0
Study 26066077 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients in FC II
Number of subjects: 0
Study 26066077 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients in FC III
Number of subjects: 0
Study 26066077 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients in FC IV
Number of subjects: 0
Study 26066323 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision-Making Renal Supportive Care communication intervention
Number of subjects: 0
Study 26066323 — intervention group
Group type: COMPARATOR
Intervention: Control group (retrospective cohort)
Number of subjects: 0
Study 26066744 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy group
Number of subjects: 102
Study 26066744 — intervention group
Group type: COMPARATOR
Intervention: Glaucoma group
Number of subjects: 102
Study 26066765 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim treatment for up to 4 years
Number of subjects: 407
Study 26066765 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim treatment
Number of subjects: 407
Study 26066791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cueing innovations for pressure ulcer prevention
Number of subjects: 0
Study 26067854 — intervention group
Group type: COMPARATOR
Intervention: CAD but no angina
Number of subjects: 4128
Study 26067854 — intervention group
Group type: COMPARATOR
Intervention: CAD and angina
Number of subjects: 4128
Study 26068100 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine
Number of subjects: 540
Study 26068100 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-SAM children)
Number of subjects: 540
Study 26068287 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26068543 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 6 months
Number of subjects: 12
Study 26068543 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after 6 months of aerobic exercise
Number of subjects: 12
Study 26068543 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis post-detraining
Number of subjects: 12
Study 26068862 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed Cardiovascular Autonomic Neuropathy (CAN)
Number of subjects: 557
Study 26068862 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Cardiovascular Autonomic Neuropathy (CAN)
Number of subjects: 557
Study 26068862 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with CAN
Number of subjects: 557
Study 26068866 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet transplantation alone (ITA)
Number of subjects: 44
Study 26068866 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet after kidney transplantation (IAK)
Number of subjects: 44
Study 26068866 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 44
Study 26069234 — intervention group
Group type: COMPARATOR
Intervention: Circulating FABP4 in patients with ST-segment-elevation myocardial infarction (24.9 ng/mL)
Number of subjects: 820
Study 26069234 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated FABP4 in patients with ACS
Number of subjects: 820
Study 26069234 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating FABP4
Number of subjects: 820
Study 26069234 — intervention group
Group type: COMPARATOR
Intervention: Baseline FABP4 in asymptomatic individuals
Number of subjects: 820
Study 26069305 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-DCFBC PET
Number of subjects: 13
Study 26069305 — intervention group
Group type: COMPARATOR
Intervention: MR imaging
Number of subjects: 13
Study 26070003 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescreening and screening process for fecal donors
Number of subjects: 116
Study 26070003 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool testing
Number of subjects: 116
Study 26070003 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood testing
Number of subjects: 116
Study 26070003 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening interview
Number of subjects: 116
Study 26070008 — intervention group
Group type: EXPERIMENTAL
Intervention: High-confidence NBI evaluation for adenoma in diminutive lesions
Number of subjects: 284
Study 26070008 — intervention group
Group type: EXPERIMENTAL
Intervention: High-confidence characterization of diminutive polyps
Number of subjects: 284
Study 26070008 — intervention group
Group type: EXPERIMENTAL
Intervention: NPV for adenoma in the rectosigmoid
Number of subjects: 284
Study 26070531 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKIs
Number of subjects: 4196
Study 26070531 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy
Number of subjects: 4196
Study 26070683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258), 500mg orally once daily for five consecutive days, followed by a 2-day rest every week
Number of subjects: 40
Study 26070683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258)
Number of subjects: 40
Study 26071031 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 6906
Study 26071053 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP treatment (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone) followed by two cycles of R (R-CHOP-14)
Number of subjects: 123
Study 26071053 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP treatment
Number of subjects: 123
Study 26071053 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of CD5
Number of subjects: 123
Study 26071053 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of FOXP1
Number of subjects: 123
Study 26071091 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep tissue electrical pain stimulation by needle electrodes in the right groin (rectus muscle, ilioinguinal/iliohypogastric nerve and perispermatic cord)
Number of subjects: 19
Study 26071091 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep tissue electrical pain stimulation
Number of subjects: 19
Study 26071133 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors (anxiety)
Number of subjects: 1379
Study 26071133 — intervention group
Group type: EXPERIMENTAL
Intervention: Infectious gastroenteritis (IGE)
Number of subjects: 1379
Study 26071133 — intervention group
Group type: EXPERIMENTAL
Intervention: Th2 cytokine phenotype at time of infection
Number of subjects: 1379
Study 26071133 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell numbers
Number of subjects: 1379
Study 26071191 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex PCR (mPCR)
Number of subjects: 40
Study 26071191 — intervention group
Group type: COMPARATOR
Intervention: Conventional microbiology (cMD)
Number of subjects: 40
Study 26071868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (200 mg/day to 1000 mg/day, days -8 to -3) + Gemcitabine (10 mg/m²/minute over 4.5 hours, days -8 and -3) + Busulfan (targeted 4000 μM-minute/day, days -8 to -5) + Melphalan (60 mg/m²/day, days -3 and -2) + Rituximab (375 mg/m², days +1 and +8 for CD20(+) tumors)
Number of subjects: 78
Study 26072112 — intervention group
Group type: EXPERIMENTAL
Intervention: hFABP combined with NT-proBNP
Number of subjects: 401
Study 26072112 — intervention group
Group type: EXPERIMENTAL
Intervention: hFABP (4th quartile)
Number of subjects: 401
Study 26072112 — intervention group
Group type: EXPERIMENTAL
Intervention: hFABP
Number of subjects: 401
Study 26072112 — intervention group
Group type: COMPARATOR
Intervention: TnI
Number of subjects: 401
Study 26072149 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin at 4 mg/kg/day
Number of subjects: 55
Study 26072403 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible caspase 9 (iC9) system with AP1903
Number of subjects: 0
Study 26072932 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Ling Granule (15-22.5 g/day)
Number of subjects: 603
Study 26072932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride (200-400 mg/day)
Number of subjects: 603
Study 26072932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 26072932 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 603
Study 26073352 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib oral solution (OS) 25 mg
Number of subjects: 35
Study 26073352 — intervention group
Group type: COMPARATOR
Intervention: Alisertib powder-in-capsule (PIC) 50 mg
Number of subjects: 35
Study 26073352 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib oral solution (OS)
Number of subjects: 35
Study 26073352 — intervention group
Group type: COMPARATOR
Intervention: Alisertib powder-in-capsule (PIC)
Number of subjects: 35
Study 26073451 — intervention group
Group type: EXPERIMENTAL
Intervention: KRN23 (0.05, 0.10 ± 0.01, 0.28 ± 0.06, and 0.48 ± 0.16 mg/kg administered subcutaneously every 28 days)
Number of subjects: 28
Study 26073658 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation
Number of subjects: 0
Study 26073658 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative follow-up
Number of subjects: 0
Study 26074476 — intervention group
Group type: EXPERIMENTAL
Intervention: CRSwNP
Number of subjects: 63
Study 26074476 — intervention group
Group type: EXPERIMENTAL
Intervention: CRSsNP
Number of subjects: 63
Study 26074476 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study 26074990 — intervention group
Group type: EXPERIMENTAL
Intervention: IQP-VV-102
Number of subjects: 120
Study 26074990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26075081 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of phylloquinone three times per week
Number of subjects: 0
Study 26075081 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration three times per week
Number of subjects: 0
Study 26075389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphoric group
Number of subjects: 82
Study 26075389 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 82
Study 26075496 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel TNXB missense variant c.12174C>G (p.C4058W)
Number of subjects: 246
Study 26075496 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously described TNXA/TNXB chimeras
Number of subjects: 246
Study 26075496 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel TNXB variant
Number of subjects: 246
Study 26075496 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal tenascin-X protein expression in dermal fibroblasts
Number of subjects: 246
Study 26076437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index (ODI) score of 22 or less (favorable outcome group)
Number of subjects: 157
Study 26076437 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Pain Sensitivity Questionnaire (PSQ) score
Number of subjects: 157
Study 26076437 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PSQ score
Number of subjects: 157
Study 26076437 — intervention group
Group type: EXPERIMENTAL
Intervention: ODI score
Number of subjects: 157
Study 26076696 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 robotic exoskeleton for gait rehabilitation
Number of subjects: 3
Study 26076936 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularisation within 90 days of CCTA
Number of subjects: 23745
Study 26076936 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 23745
Study 26076936 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) in patients with severe CAD (≥70% stenosis)
Number of subjects: 23745
Study 26076936 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in patients with severe CAD (≥70% stenosis)
Number of subjects: 23745
Study 26077240 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg twice a day for 7 days on 21-day cycles
Number of subjects: 37
Study 26077415 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine premedication
Number of subjects: 1632
Study 26077415 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 1632
Study 26077415 — intervention group
Group type: COMPARATOR
Intervention: Concomitant immunosuppressant or corticosteroids
Number of subjects: 1632
Study 26077415 — intervention group
Group type: COMPARATOR
Intervention: Antihistamines, intravenous steroids, and acetaminophen as preventative premedication
Number of subjects: 1632
Study 26077584 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge-detected IMT
Number of subjects: 5468
Study 26077584 — intervention group
Group type: COMPARATOR
Intervention: Manual-traced IMT
Number of subjects: 5468
Study 26077584 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge-detected IMT (after additional adjustment for clinic site and reader)
Number of subjects: 5468
Study 26078575 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol's chromoendoscopy-guided confocal laser endomicroscopy (CLE)
Number of subjects: 52
Study 26078575 — intervention group
Group type: COMPARATOR
Intervention: Chromoendoscopy-guided biopsy
Number of subjects: 52
Study 26078787 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin D levels in men
Number of subjects: 698
Study 26078787 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PTH levels in women
Number of subjects: 698
Study 26078787 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-diabetic individuals)
Number of subjects: 698
Study 26079418 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal diagnostic scenario for MCI classification
Number of subjects: 153